Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/ Refractory Small Cell Lung Cancer

This study evaluates a fenretinide phospholipid suspension for the treatment of small cell lung cancer (SCLC).

Trial Details

NCT ID
NCT06922539
Phase
PHASE1
Sponsor
SciTech Development, Inc.
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Fenretinide
Locations (sample)
  • Los Angeles, California, United States|34.05223,-118.24368
  • Detroit, Michigan, United States|42.33143,-83.04575

Key Eligibility Criteria

  • Small cell lung cancer (SCLC).
  • Patients must all have at least one measurable disease site using RECIST version 1.1 criteria.
  • Patients must have relapsed or refractory disease to prior treatment with platinum-based chemotherapy ± immunotherapy. There is no limit on the num…
  • Relapsed/refractory disease of any stage if incurable in nature, is eligible for enrollment.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →